Kalydeco (Ivacaftor)

Ivacaftor is a medicine for cystic fibrosis in people who have certain gene changes. It is taken by mouth as a pill or as granules mixed into soft food. It helps a faulty protein on cells open up so salt and water can move properly, which keeps mucus thinner.

Brand names:Kalydeco
Medication

What people taking Kalydeco (Ivacaftor) report

Every report comes from a Lived member, sent anonymously.

Have you tried Kalydeco (Ivacaftor) for Cystic Fibrosis?

NameHow it went

About Kalydeco (Ivacaftor)

What It's For

Ivacaftor, sold as Kalydeco, is a prescription medicine for cystic fibrosis (CF), an inherited disease that makes mucus thick and sticky, clogging the lungs and affecting the pancreas, intestines and other organs. Most CF treatments manage the consequences: clearing mucus, treating infections and supporting nutrition. Ivacaftor belongs to a newer group called CFTR modulators, which act on the faulty protein behind the disease, the cystic fibrosis transmembrane conductance regulator (CFTR). Kalydeco is approved for people aged 1 month and older who have at least one change (mutation) in the CFTR gene that responds to ivacaftor. Whether it can help depends on that genetic result, so a CF gene test, with confirmation by sequencing when the test calls for it, comes before treatment. The best known responsive mutation is G551D, but the label lists many others. Ivacaftor taken alone does not meaningfully help people who have two copies of the F508del mutation: in a 16-week trial in that group, lung function differed from placebo by less than 2 percentage points, which was not statistically significant. Ivacaftor is also one of the ingredients in combination medicines, most notably Trikafta (elexacaftor, tezacaftor and ivacaftor), which cover a wider range of mutations, including F508del. In studies, Kalydeco was taken on top of people's usual CF care rather than in place of it.

How It Works

The CFTR gene carries the instructions for the CFTR protein, a channel on the surface of cells lining the airways, gut, pancreas, sweat glands and other organs. When the channel opens, chloride (one part of salt) moves across the cell surface, which helps keep mucus and other secretions thin. In CF the channel is missing, scarce or does not open properly, so secretions thicken. Ivacaftor is a CFTR potentiator: it helps channels that have already reached the cell surface stay open more of the time, so more chloride can pass. That is why it works well for gating mutations such as G551D, where the protein reaches the surface but rarely opens, and why it cannot do much on its own when very little protein reaches the surface. In Trikafta, the other two ingredients help more protein reach the surface, and ivacaftor then helps it open. How much a person benefits depends on how much CFTR protein their cells make and how well their particular mutation responds. One visible sign of the effect is the sweat test, the same test used to help diagnose CF, which measures chloride in sweat. Levels usually fall on ivacaftor because the channel is working better.

Dosage & Administration

People aged 6 and older usually take one 150 mg tablet every 12 hours, swallowed whole. Children from 1 month to under 6 years take oral granules instead: the packet strength depends on age and weight, and the whole packet is mixed with one teaspoon of soft food or liquid (such as applesauce, yogurt, breast milk or formula) at or below room temperature, then finished within one hour. Every dose should be taken with food that contains fat, such as eggs, butter, peanut butter, cheese or whole-milk dairy, because the body absorbs ivacaftor much better that way. A typical CF diet usually provides enough. If a dose is missed and fewer than 6 hours have passed, take it with fat-containing food as soon as possible; if more than 6 hours have passed, skip it and take the next dose at the usual time. The prescriber lowers the dose, sometimes to once a day or less often, for people with moderate or severe liver disease or who take certain interacting medicines. Kalydeco is not recommended for babies under 1 month, or for babies under 6 months who have any liver problem or take those interacting medicines.

Side Effects

The most common side effects in studies were headache, colds and other upper respiratory infections, a stuffy nose, nausea and rash. Some people feel dizzy; anyone who does should avoid driving or operating machinery until it passes. Stomach pain and low blood sugar were among the serious problems that occurred more often with ivacaftor than with placebo. New or worsening anxiety, low mood, sleep problems, unusual changes in behavior or thinking, or thoughts of suicide have been reported in adults and children, including people with no history of these problems, often within the first three months. Contact the care team right away if any of these appear. Raised pressure around the brain (intracranial hypertension) has been reported with medicines containing the same or similar ingredients. An unusual headache, blurred or double vision, or vision loss should be reported to the care team right away. Serious allergic reactions, including anaphylaxis, are rare. Stop taking ivacaftor and get emergency care for hives, swelling of the face, chest tightness or wheezing.

Interactions & Warnings

Ivacaftor is broken down by a liver enzyme called CYP3A, so medicines that change that enzyme change how much ivacaftor reaches the body. Some antifungal medicines (such as fluconazole, itraconazole and voriconazole) and antibiotics (clarithromycin and erythromycin) raise ivacaftor levels (fluconazole roughly tripled them in a study), so the dose is usually reduced while they are taken. Grapefruit and grapefruit juice have a similar effect and should be avoided. In the other direction, rifampin and rifabutin (tuberculosis antibiotics), the seizure medicines carbamazepine, phenytoin and phenobarbital, and the herbal supplement St. John's wort lower ivacaftor levels sharply, which can make it much less effective, so using them together is not recommended. Because people with CF often take antibiotics and antifungals, check with the CF team or pharmacist whenever a new prescription is started. Ivacaftor can also raise levels of some other medicines. People taking warfarin, a blood thinner, need closer checks of their INR (a blood test of clotting time). Extra caution is needed with digoxin (a heart medicine), the transplant medicines cyclosporine and tacrolimus, and the diabetes medicines glipizide and glimepiride. Liver enzymes can rise during treatment, which is why blood tests are part of routine care, and treatment is paused if they rise too high. Human data in pregnancy and breastfeeding are limited, so anyone pregnant, planning pregnancy or breastfeeding should weigh the options with the CF team.

What to Expect

In the main trial of people aged 12 and older with the G551D mutation, lung function measured by FEV1 (how much air a person can forcefully blow out in one second, compared with what is expected for their age, sex and height) improved by about 10.6 percentage points more than with placebo. The improvement appeared within two weeks and held through 48 weeks. People taking ivacaftor also had fewer lung flare-ups, better breathing symptoms, weight gain and lower sweat chloride. Results vary between people and mutations, so the CF team tracks lung function, symptoms and sometimes sweat chloride to judge the response. Ivacaftor improves how the faulty protein works but does not cure CF. It is taken alongside the usual airway clearance, inhaled treatments, enzymes and nutrition plan unless the CF team changes them. Liver blood tests are done before starting, every 3 months during the first year and yearly after that. Children should have an eye exam before starting and follow-up exams, because cataracts (clouding of the eye's lens) have been reported in children taking ivacaftor.

Questions to Ask Your Doctor

  1. 1.Does my CFTR mutation respond to ivacaftor alone, or would a combination such as Trikafta suit my genetics better?
  2. 2.How will we measure whether it is working, and when should I expect to see a change?
  3. 3.Which of my current or future antibiotics, antifungals or supplements would require a dose change?
  4. 4.Which of my other CF treatments should I keep, and could any be reduced if I respond well?
  5. 5.What should I do if I notice mood, sleep or vision changes, and who do I contact?

Last reviewed • Oct 2026

Educational content, not medical advice.